SCHEMBL121124

SCHEMBL121124

COC(=O)C(C)CCc1ccccc1

nearest known ligand 0.65

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.65
SMN1; SMN2 Q16637 4/20 0.54
KMT2A Q03164 4/20 0.53
MEN1 O00255 1/20 0.53
HTT P42858 1/20 0.53
HPGD P15428 1/20 0.53
ALDH1A1 P00352 4/20 0.51
MAPT P10636 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
THRB P10828 1/20 0.50
CYP2C9 P11712 1/20 0.50
CYP2C19 P33261 1/20 0.50
HSD17B10 Q99714 1/20 0.50
NPC1 O15118 1/20 0.49
RAB9A P51151 1/20 0.49
CNR2 P34972 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6574637 1.00 TSHR (0.65) TSHRSMN1; SMN2KMT2AMEN1HTT
SCHEMBL4200709 0.90 TSHR (0.53) TSHRSMN1; SMN2KMT2AHPGDALDH1A1
SCHEMBL16379302 0.90 TSHR (0.53) TSHRSMN1; SMN2KMT2AHPGDALDH1A1
SCHEMBL30423678 0.88 FAAH (0.52) TSHRKMT2AHPGDALDH1A1CYP2C9
SCHEMBL18300369 0.86 TSHR (0.57) TSHRSMN1; SMN2KMT2AMEN1HTT
SCHEMBL25842763 0.84 TSHR (0.51) TSHRSMN1; SMN2KMT2AMEN1HTT
SCHEMBL8224624 0.84 SMN1; SMN2 (0.60) TSHRSMN1; SMN2KMT2AMEN1HTT
SCHEMBL29006983 0.84 TSHR (0.58) TSHRSMN1; SMN2KMT2AMEN1HTT
SCHEMBL265567 0.84 SMN1; SMN2 (0.60) TSHRSMN1; SMN2KMT2AMEN1HTT
SCHEMBL29232860 0.84 TSHR (0.58) TSHRSMN1; SMN2KMT2AMEN1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250325463-A1 COMPOSITIONS (III) SYMRISE AG (DE) 2025-10-23 US claimed
EP-4602141-A1 A FRAGRANCE MIXTURE (VI) Symrise AG (DE) 2025-08-20 EP claimed
EP-4532646-A1 A FRAGRANCE MIXTURE (V) Symrise AG (DE) 2025-04-09 EP claimed
US-20250099349-A1 A FRAGRANCE MIXTURE SYMRISE AG (DE) 2025-03-27 US claimed
EP-4519403-A1 A FRAGRANCE MIXTURE (V) Symrise AG (DE) 2025-03-12 EP claimed
EP-4473079-A1 A FRAGRANCE MIXTURE Symrise AG (DE) 2024-12-11 EP claimed
EP-4472606-A1 COMPOSITIONS (III) Symrise AG (DE) 2024-12-11 EP claimed
US-20240358611-A1 COMPOSITIONS SYMRISE AG (DE) 2024-10-31 US claimed
EP-4429465-A1 COMPOSITIONS COMPRISING TRPM8 AGONISTIC COOLING AGENTS Symrise AG (DE) 2024-09-18 EP claimed
EP-4387587-A1 COMPOSITIONS Symrise AG (DE) 2024-06-26 EP claimed
US-8962057-B2 Methods for improving taste and oral care compositions with improved taste THE PROCTER & GAMBLE COMPANY (US) 2015-02-24 US claimed
EP-2424621-A2 METHODS FOR IMPROVING TASTE AND ORAL CARE COMPOSITIONS WITH IMPROVED TASTE The Procter & Gamble Company (US) 2012-03-07 EP claimed
US-20110118217-A1 Agonists for Antimicrobial Peptide Systems AKTHELIA PHARMACEUTICALS (IS) 2011-05-19 US claimed
US-20110105544-A1 CARBOXYLIC DERIVATIVES FOR USE IN THE TREATMENT OF CANCER CRYSTAX PHARMACEUTICALS, S.L. (ES) 2011-05-05 US claimed
CN-101959429-A Agonists of antimicrobial peptide systems AKTHELIA PHARMACEUTICALS 2011-01-26 CN claimed
WO-2010126753-A2 METHODS FOR IMPROVING TASTE AND ORAL CARE COMPOSITIONS WITH IMPROVED TASTE THE PROCTER & GAMBLE COMPANY (US) 2010-11-04 WO claimed
US-20100278991-A1 Methods for Improving Taste and Oral Care Compositions With Improved Taste THE PROCTER & GAMBLE COMPANY 2010-11-04 US claimed
EP-2237684-A2 AGONISTS FOR ANTIMICROBIAL PEPTIDE SYSTEMS Akthelia Pharmaceuticals (IS) 2010-10-13 EP claimed
WO-2009087474-A2 AGONISTS FOR ANTIMICROBIAL PEPTIDE SYSTEMS AKTHELIA PHARMACEUTICALS (IS) 2009-07-16 WO claimed
WO-2009080722-A2 CARBOXYLIC DERIVATIVES FOR USE IN THE TREATMENT OF CANCER CRYSTAX PHARMACEUTICALS, S.L. (ES) 2009-07-02 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240358611-A1 COMPOSITIONS AZI2, NISCH, CIP2A TSHR 4086/4885SMN1; SMN2 955/4885KMT2A 617/4885
US-20110118217-A1 Agonists for Antimicrobial Peptide Systems VIP, GLP1R, MAVS TSHR 2225/4885SMN1; SMN2 3320/4885KMT2A 4643/4885
US-20250099349-A1 A FRAGRANCE MIXTURE PTMS, EP300, TRPA1 TSHR 4083/4885SMN1; SMN2 4713/4885KMT2A 804/4885
US-20110105544-A1 CARBOXYLIC DERIVATIVES FOR USE IN THE TREATMENT OF CANCER AKR1C3, TPD52L2, HCCS TSHR 1505/4885SMN1; SMN2 2869/4885KMT2A 2127/4885
US-20250325463-A1 COMPOSITIONS (III) NISCH, TAS1R3, TAS2R3 TSHR 2980/4885SMN1; SMN2 1800/4885KMT2A 2977/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.